#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	12886	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2083	613.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1719	1719	T	666	T	619	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	12886	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2083	613.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1453	1453	C	708	C	661	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	12886	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2083	613.5	0	HET	.	.	.	G1415A	.	1415	1415	G	1684	1684	G	670	G,A	485,151	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23746	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3750	631.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1860	1860	A	799	A,G	757,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23746	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3750	631.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2494	2494	C	720	C	664	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23746	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3750	631.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2568	2568	A	720	A	681	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23746	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3750	631.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3120	3120	C	698	C	658	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1780	folP	855	855	100.0	folP.l15.c4.ctg.1	1428	123.8	1	SNP	p	R229S	1	.	.	685	687	AGC	960	962	AGC	191;191;189	A;G;C	178;181;178	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4562	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3522	129.2	1	SNP	p	S91F	1	.	.	271	273	TTC	691	693	TTC	165;165;166	T;T;C	151;152;152	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4562	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3522	129.2	1	SNP	p	D95G	1	.	.	283	285	GGC	703	705	GGC	157;156;156	G;G;C	143;144;144	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4562	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3522	129.2	1	SNP	p	G95N	0	.	.	283	285	GGC	703	705	GGC	157;156;156	G;G;C	143;144;144	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1422	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1360	103.7	1	SNP	p	G45D	0	.	.	133	135	GGC	617	619	GGC	185;185;187	G;G;C	171;170;171	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	728	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	1010	71.7	0	.	n	.	0	A197.	DEL	197	197	A	603	603	A	174	A	166	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4380	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3170	137.6	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1556	1558	GTC	187;187;189	G;T;C	176;176;178	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4380	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3170	137.6	1	SNP	p	D86N	0	.	.	256	258	GAC	662	664	GAC	171;173;177	G;A;C	159;162;168	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4380	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3170	137.6	1	SNP	p	R87I	0	.	.	259	261	CGT	665	667	CGT	176;176;176	C,A;G,A;T	165,1;166,1;165	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4380	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3170	137.6	1	SNP	p	S87R	1	.	.	259	261	CGT	665	667	CGT	176;176;176	C,A;G,A;T	165,1;166,1;165	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4380	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3170	137.6	1	SNP	p	R87W	0	.	.	259	261	CGT	665	667	CGT	176;176;176	C,A;G,A;T	165,1;166,1;165	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4380	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3170	137.6	1	SNP	p	S88P	0	.	.	262	264	TCC	668	670	TCC	176;178;177	T;C;C	166;166;165	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3924	parE	1986	1986	99.95	parE.l6.c30.ctg.1	2737	142.8	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1330	1332	TGC	186;186;186	T,C,G;G;C	172,2,1;178;179	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3924	parE	1986	1986	99.95	parE.l6.c30.ctg.1	2737	142.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1540	1542	GGC	212;211;211	G;G;C	194;195;190	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3646	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2394	151.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1271	1273	GCA	199;199;200	G;C;A	178;178;186	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3646	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2394	151.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1274	1276	ATC	200;203;205	A;T;C	188;191;190	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3646	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2394	151.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1286	1288	GTG	203;203;204	G,T;T;G	190,1;190;187	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3646	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2394	151.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1286	1288	GTG	203;203;204	G,T;T;G	190,1;190;187	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3646	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2394	151.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1790	1792	ACC	183;185;185	A;C;C	163;167;171	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3646	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2394	151.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1844	1846	GCG	167;168;166	G;C;G	149;134;144	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3646	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2394	151.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1844	1846	GCG	167;168;166	G;C;G	149;134;144	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3646	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2394	151.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1967	1969	GGC	170;166;165	G;G;C	160;154;151	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3646	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2394	151.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1976	1978	GGC	164;162;162	G;G;C	148;150;151	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3646	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2394	151.7	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1994	1996	TCG	166;169;168	T,G;C;G	116,4;135;147	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4926	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3129	156.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1666	1668	CCG	214;211;212	C;C,G;G	182;186,1;181	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1930	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1805	106.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	488	488	C	129	C	116	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2620	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1554	166.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	364	366	GAA	219;219;221	G;A;A	204;207;206	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2620	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1554	166.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	652	654	GAT	193;193;194	G;A;T	177;175;175	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2620	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1554	166.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	775	777	TCA	217;216;217	T;C;A	206;206;207	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2620	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1554	166.9	0	.	p	.	0	Y216F	NONSYN	646	648	TAT	898	900	TTT	209;209;210	T;T,A;T	198;199,1;202	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2620	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1554	166.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	904	906	GTC	210;209;210	G,A;T;C	194,2;192;196	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2620	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1554	166.9	0	.	p	.	0	G255E	NONSYN	763	765	GGA	1015	1017	GAA	183;184;184	G;A;A	175;177;176	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2620	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1554	166.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1234	1236	GCA	198;197;196	G;C;A	185;186;187	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2620	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1554	166.9	1	SNP	p	G120K	1	.	.	358	360	AAG	610	612	AAG	196;196;196	A;A;G	189;189;188	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2620	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1554	166.9	1	SNP	p	A121D	1	.	.	361	363	GAC	613	615	GAC	193;193;193	G;A;C	184;185;184	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2620	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	1554	166.9	1	SNP	p	D121N	0	.	.	361	363	GAC	613	615	GAC	193;193;193	G;A;C	184;185;184	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9678	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	5026	192.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2109	2111	AAT	213;212;211	A;A;T	197;195;193	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	950	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1109	85.0	1	SNP	p	V57M	1	.	.	169	171	ATG	522	524	ATG	189;189;189	A;T;G	182;180;183	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
